Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Tissium S.A.. (11/20/19). "Press Release: Tissium Closes €39M Series B Funding Round". Paris.

Organisations Organisation Tissium S.A.
  Group Tissium (Group)
  Organisation 2 BNP Paribas Développement
  Group BNP Paribas (Group)
Products Product polymers
  Product 2 venture capital
Index term Index term Tissium–SEVERAL: investment, 201911 financing round Series B €38.75m from EIB + French investors
Persons Person Bancel, Christophe (Gecko Biomedical 201603 CEO + Co-Founder)
  Person 2 Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)

TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today it has raised €38.75 million ($42.78 million) in a Series B round of funding. This funding round comprises new investors BNP Paribas Développement, the European Investment Fund (EIF), M&L Investments, ValQuest Partners in addition to TISSIUM’s returning investors Bpifrance, CM-CIC Innovation, CapDecisif Management, Omnes Capital and Sofinnova Partners.

The funding raised in this round will be used to support the Company’s global expansion of its platform of polymers across a variety of therapeutic fields, including nerve repair, cardiovascular and gastroenterology, among others.

The TISSIUM platform leverages proprietary technology, initially developed at the Massachusetts Institute of Technology (MIT) & Brigham and Women’s Hospital, Harvard Medical School, that serves as the foundation of a family of fully synthetic, biomorphic and programmable polymers. These polymers are designed to be used inside the body as sealants, adhesives, barriers, plugs or as a vehicle for drug delivery, as well as implantable devices created outside of the body using 3D printing technology.

In addition to supporting the growth of the platform, the funding is expected to support the broader strategy of creating a streamlined clinical development and regulatory process across multiple geographies. While the company remains headquartered in Paris, these efforts will also be focused towards the U.S. out of its newly opened Boston affiliate office. Streamlined innovation and product development will also be simplified as a result of the completion of TISSIUM’s state-of-the-art manufacturing facility in Lille, France.

In addition, following the completion of the Series B, Jay Watkins, a serial Medtech entrepreneur and executive, is joining TISSIUM’s Board of Directors as Independent Chairman.

Christophe Bancel, CEO of TISSIUM, said: « This new round of funding is a testament to the support we continue to receive from investors for our strategy and vision for the broad TISSIUM ecosystem of products that we have in development. We look forward to moving swiftly towards multiple verticals and expanding into new clinical fields in the coming months. We are thrilled to have Jay joining our board as Chairman. He brings tremendous experience and depth in building innovative Medtech companies into next generations leaders and will allow us to shape and expend our ecosystem into multiple verticals. I take the opportunity to thank our co-founder, Bernard Gilly, co-founder and Chairman of iBionext, who has led the company as its Chairman since our inception. »

Jay Watkins, Chairman of TISSIUM, added: « I am delighted to join TISSIUM as Chairman. I have been impressed with the breadth of applications for its biomorphic programmable polymers across a wide range of therapeutic fields. The organization has already demonstrated its ability to innovate and create novel product opportunities and I look forward to working with the team to extend our impact in the Medtech space. »


TISSIUM is a privately-owned life sciences company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.

The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customization to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.

The Company’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more information, please visit: and @TISSIUMtech.



Brice Epry – Chief of Staff
Tel: +33 1 76 21 72 28
Twitter: @TISSIUMtech

Marion Janic
Tel: +1 212 223 4017

Record changed: 2023-07-18


Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for Tissium (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top